Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCT06085924 | Registry Identifier | ClinicalTrials.gov |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn about:
This is a study of two groups of COVID-19 patients in Taiwan.
In Group 1 the below participants were included in the study:
In Group 2 the below participants were included in the study:
Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.
The study will look at:
This study will help to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 - Cases of patients registered in the databases of all ages | Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021 |
| |
| Cohort 2 - Cases of patients registered in the databases of ≥12 years of age | Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SoC | Drug | COVID-19 treatment as per government guidance |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU) | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support |
| Measure | Description | Time Frame |
|---|---|---|
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Required Hospital Admission | 01 January 2021 to 31 December 2021 | |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Hospital Admission | 01 January 2021 to 31 December 2021 |
Not provided
Cohort 1:
Inclusion Criteria:
Exclusion Criteria:
Cohort 2:
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Study data will be retrospectively collected from the National Health Insurance Research Database (NHIRD). The NHIRD is a nation-wide claims database in Taiwan, which contains anonymized patient-level claims data covering 99.9% of the entire 23 million Taiwanese population.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Taiwan | Taipei | Taiwan |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Disease description | Other | No intervention |
|
| 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome | 01 January 2021 to 31 December 2021 |
| Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir | 01 January 2022 to 31 December 2022 |
| Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission | 01 January 2021 to 31 December 2021 |
| Cohort 1: Incidence Proportion of ICU Admissions Among COVID-19 Patients Requiring Hospitalization Per Age Range | 01 January 2021 to 31 December 2021 |
| Cohort 1: Clinical Characteristics Associated to ICU Admission Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Risk Factors Associated to ICU Admission Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Clinical Characteristics Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Risk Factors Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Mortality Rate Associated to Ventilatory Support Among Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 1: Average Length of Stay (LOS) of Hospitalized COVID-19 Patients | 01 January 2021 to 31 December 2021 |
| Cohort 2: Incidence for severe COVID-19 Overall | 01 January 2022 to 31 December 2022 |
| Cohort 2: Incidence for severe COVID-19 By Risk Group | 01 January 2022 to 31 December 2022 |
| Cohort 2: Incidence for severe COVID-19 By Time Period | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 Overall | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 By Risk Group | 01 January 2022 to 31 December 2022 |
| Cohort 2: Relative Risk for severe COVID-19 By Time Period | 01 January 2022 to 31 December 2022 |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |